## Prognostic Factors in Retinoblastoma ### Overview Retinoblastoma prognosis is determined by the extent of intraocular disease, extraocular spread, and histopathologic features. The most critical discriminator between favorable and unfavorable prognosis is the presence or absence of extraocular extension. ### Prognostic Classification: Intraocular vs Extraocular Disease | Prognostic Factor | Favorable Prognosis | Unfavorable Prognosis | |---|---|---| | **Extraocular extension** | Absent (confined to retina/globe) | Present (optic nerve, sclera, orbit, distant metastases) | | **Optic nerve involvement** | Limited to lamina cribrosa | Extends beyond lamina cribrosa | | **Choroidal invasion** | Absent or limited | Massive | | **Anterior chamber involvement** | Absent | Present | | **Survival (5-year)** | >95% with chemotherapy | <50% if metastatic | | **Globe salvage** | Possible with chemotherapy | Often requires enucleation | **Key Point:** Tumor confined to the retina and choroid WITHOUT extraocular extension is the single most important favorable prognostic factor. Once the tumor breaches the sclera or involves the optic nerve beyond the lamina cribrosa, prognosis deteriorates dramatically. ### International Classification of Retinoblastoma (Murphree) ```mermaid flowchart TD A[Retinoblastoma]:::outcome --> B{Extent of disease?}:::decision B -->|Intraocular only| C[Group A-D]:::outcome C -->|A: Small, fovea-sparing| D[Excellent prognosis]:::action C -->|B-D: Larger, foveal/optic disc involvement| E[Good-Fair prognosis]:::action B -->|Extraocular extension| F[Group E]:::urgent F -->|Optic nerve, sclera, orbit| G[Poor prognosis]:::urgent F -->|Distant metastases| H[Very poor prognosis]:::urgent ``` ### High-Yield Prognostic Thresholds **High-Yield:** The presence of optic nerve involvement BEYOND the lamina cribrosa (microscopic invasion) is a major adverse prognostic factor. However, tumor confined to the retina without any extraocular spread is the most favorable scenario. **Clinical Pearl:** Enucleation is reserved for eyes with advanced intraocular disease (Group E) or those that fail chemotherapy. Chemotherapy-responsive tumors confined to the globe have >95% survival. Extraocular disease requires systemic chemotherapy and carries significantly worse outcomes. ### Why Extraocular Extension Is the Key Discriminator 1. **Intraocular disease:** Chemotherapy (systemic and intra-arterial) and external beam radiation can achieve excellent control. 2. **Extraocular disease:** Requires aggressive multimodal therapy (chemotherapy + radiation ± enucleation) with worse outcomes due to risk of dissemination. 3. **Metastatic disease:** Bone, bone marrow, CNS involvement → 5-year survival <10% despite intensive therapy. [cite:Shields & Shields Retinoblastoma Ch 8] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.